Welcome to the Edwards Lifesciences Securities Litigation Website
The information contained on this website is only a summary of the information presented in more detail in the Notice of (I) Pendency of Class Action and Proposed Settlement; (II) Settlement Hearing; and (III) Motion for Attorneys’ Fees and Litigation Expenses (the “Notice”). Because this website is just a summary, you should review the Notice for additional details.
Summary of the Action and Settlement
This website relates to a proposed Settlement of claims in a pending securities class action (the “Action”) alleging that Edwards Lifesciences Corporation (“Edwards”) and its Chief Executive Officer, Bernard J. Zovighian (together, “Defendants”) violated the federal securities laws by making materially false and misleading statements during the Class Period (defined below) concerning the growth prospects of Edwards’ core product, its transcatheter aortic valve replacement (“TAVR”) platform. A more detailed description of the Action is set forth in the Notice. Defendants deny all allegations in the Action and deny any violations of the federal securities laws.
Subject to Court approval, Lead Plaintiffs City of Fort Lauderdale Police & Firefighters’ Retirement System and Louisiana Sheriffs’ Pension & Relief Fund (together, “Lead Plaintiffs”), on behalf of the Settlement Class, have agreed to settle the Action in exchange for a cash payment of $39,000,000.
If you are a member of the Settlement Class, you are subject to the Settlement, unless you timely and validly request to be excluded. The Settlement Class consists of:
all persons or entities who purchased or otherwise acquired Edwards common stock during the period from February 6, 2024, through July 24, 2024, inclusive (the “Class Period”), and were damaged thereby.
Certain persons and entities are excluded from the Settlement Class by definition (see paragraph 30 of the Notice). Also excluded from the Settlement Class are any persons and entities that submit a request for exclusion from the Settlement Class that is accepted by the Court.
Please read the Notice to fully understand your rights. Copies of the Notice and Claim Form can be found in the menu at the top of this page.
The deadline to submit a Claim Form to be eligible to participate in the proposed Settlement is December 2, 2026. Payments to eligible claimants will be made only if the Court approves the Settlement and a plan of allocation, and any appeals are resolved, and only after the completion of all claims processing. Please be patient, as this process will take some time to complete.
YOUR LEGAL RIGHTS AND OPTIONS IN THE SETTLEMENT | |
SUBMIT A CLAIM FORM POSTMARKED (IF MAILED), OR ONLINE, NO LATER THAN DECEMBER 2, 2026. | This is the only way to be eligible to receive a payment from the Settlement. If you are a Settlement Class Member and you remain in the Settlement Class, you will be bound by the Settlement as approved by the Court and you will give up any Released Plaintiffs’ Claims (defined in paragraph 35 of the Notice) that you have against Defendants and the other Released Defendants’ Parties (defined in paragraph 36 of the Notice), so it is in your interest to submit a Claim Form. In short, if you remain a Settlement Class Member, you will release all claims related to this Action, as detailed in paragraph 34 of the Notice. |
EXCLUDE YOURSELF FROM THE SETTLEMENT CLASS BY SUBMITTING A WRITTEN REQUEST FOR EXCLUSION SO THAT IT IS RECEIVED NO LATER THAN DECEMBER 2, 2026. | If you exclude yourself from the Settlement Class, you will not be eligible to receive any payment from the Settlement Fund. This is the only option that allows you ever to be part of any other lawsuit against any of the Defendants or the other Released Defendants’ Parties concerning the Released Plaintiffs’ Claims. |
OBJECT TO THE SETTLEMENT BY SUBMITTING A WRITTEN OBJECTION SO THAT IT IS RECEIVED NO LATER THAN DECEMBER 2, 2026. | If you do not like the proposed Settlement, the proposed Plan of Allocation, or the request for attorneys’ fees and Litigation Expenses, you may write to the Court and explain why you do not like them. You cannot object to the Settlement, the Plan of Allocation, or the fee and expense request unless you are a Settlement Class Member and do not exclude yourself from the Settlement Class. |
GO TO A HEARING ON DECEMBER 16, 2026, AT 1:30 P.M. PACIFIC TIME | Filing a written objection and notice of intention to appear by December 2, 2026 allows you to speak in Court, at the discretion of the Court, about the fairness of the proposed Settlement, the Plan of Allocation, and/or the request for attorneys’ fees and Litigation Expenses. If you submit a written objection, you may (but you do not have to) attend the hearing and, at the discretion of the Court, speak to the Court about your objection. |
DO NOTHING. | If you are a member of the Settlement Class and you do not submit a valid Claim Form, you will not be eligible to receive any payment from the Settlement Fund. You will, however, remain a member of the Settlement Class, which means that you give up your right to sue about the claims that are resolved by the Settlement and you will be bound by any judgments or orders entered by the Court in the Action. In short, if you remain a Settlement Class Member and do not submit a valid Claim Form, you will still release all claims related to this Action, as detailed in paragraph 34 of the Notice. |
These rights and options—and the deadlines to exercise them—are further explained in the Notice.
Please Note: The date and time of the Settlement Hearing, currently scheduled for December 16, 2026, at 1:30 p.m. Pacific Time, is subject to change without further written notice to the Settlement Class. It is also within the Court’s discretion to hold the hearing by video or telephonic conference. If you plan to attend the hearing, you should check this website, www.EdwardsLifesciencesSecuritiesLitigation.com, or with Lead Counsel to confirm no change to the date and/or time of the hearing has been made.
This website is authorized by the Court, supervised by Lead Counsel for Lead Plaintiffs and the Settlement Class, and controlled by the Settlement Administrator approved by the Court. This is the only authorized website for this case.
For more information, please use the Contact Us page, or call (833) 930-0555. You may also write to:
Edwards Lifesciences Securities Litigation
c/o Kroll Settlement Administration
P.O. Box 5014
New York, NY 10150-5014